**BubR1 allelic effects drive phenotypic heterogeneity in mosaic-variegated aneuploidy progeria syndrome**

Cynthia J. Sieben, … , Darren J. Baker, Jan M. van Deursen

*J Clin Invest.* 2019. [https://doi.org/10.1172/JCI126863](https://doi.org/10.1172/JCI126863).

**Graphical abstract**

Find the latest version:

[https://jci.me/126863/pdf](https://jci.me/126863/pdf)
**BubR1 allelic effects drive phenotypic heterogeneity in mosaic-variegated aneuploidy progeria syndrome**


Mosaic-variegated aneuploidy (MVA) syndrome is a rare childhood disorder characterized by biallelic BUBR1, CEPS7, or TRIP13 aberrations; increased chromosome missegregation; and a broad spectrum of clinical features, including various cancers, congenital defects, and progeroid pathologies. To investigate the mechanisms underlying this disorder and its phenotypic heterogeneity, we mimicked the BUBR1<sup>F<sub>1002P</sub></sup> mutation in mice (BubR1<sup>F<sub>1002P</sub></sup>) and combined it with 2 other MVA variants, BUBR1<sup>F<sub>753</sub></sup> and BUBR1<sup>H</sup>, generating a truncated protein and low amounts of wild-type protein, respectively. Whereas BubR1<sup>F<sub>753</sub></sup>L1002P and BubR1<sup>H/L1002P</sup> mice died prematurely, BubR1<sup>F<sub>1002P</sub></sup> mice were viable and exhibited many MVA features, including cancer predisposition and various progeroid phenotypes, such as short lifespan, dwarfism, lipodystrophy, sarcopenia, and low cardiac stress tolerance. Strikingly, although these mice had a reduction in total BUBR1 and spectrum of MVA phenotypes similar to that of BubR1<sup>F<sub>1002P</sub></sup> mice, several progeroid pathologies were attenuated in severity, which in skeletal muscle coincided with reduced senescence-associated secretory phenotype complexity. Additionally, mice carrying monoallelic BubR1 mutations were prone to select MVA-related pathologies later in life, with predisposition to sarcopenia correlating with mTORC1 hyperactivity. Together, these data demonstrate that BUBR1 allelic effects beyond protein level and aneuploidy contribute to disease heterogeneity in both MVA patients and heterozygous carriers of MVA mutations.

Introduction

Mosaic-variegated aneuploidy (MVA) syndrome is an autosomal recessive syndrome characterized by near-diploid aneuploidies involving multiple tissues and chromosomes (1–4). A wide variety of additional clinical features are associated with this syndrome, including microcephaly, growth and mental retardation, hypothyroidism, facial dysmorphisms, skeletal and renal anomalies, gastrointestinal and cardiac defects, childhood cancers, and early mortality (5). Three genes, all with roles in chromosome segregation, have been implicated in MVA syndrome: the mitotic checkpoint gene BUBR1 (also named BUB1B) (1, 2, 5), the centrosomal protein CEPS7 (3, 6), and the spindle assembly checkpoint (SAC) activator TRIP13 (4). The majority of patients have bi- or monoallelic mutations in BUBR1, with biallelic alterations typically involving a nonsense mutation in combination with a missense mutation in the kinase domain of the protein (2, 5). Patients with monoallelic mutations inherit a nonsense or missense mutation in combination with a hypomorphic allele, without a clear mutation, that yields low amounts of wild-type BUBR1 protein (1, 5).

Phenotypic variability is remarkably high among MVA syndrome patients, not only between patients that have mutations in different MVA genes, but also between those with distinct mutations in the same gene (2–5). Although MVA cases with BUBR1 mutations constitute the largest cohort, the overall size of this group is still too small for meaningful genotype-phenotype correlation analyses. One distinguishing feature observed in all MVA patients, regardless of the underlying mutations, is that they inaccurately segregate whole chromosomes, which has prompted speculation that the resulting aneuploidies drive the clinical features of the syndrome (7). However, decisive evidence to support this idea remains elusive. For instance, genetically engineered mice with alterations in chromosomal instability (CIN) genes are often predisposed to tumors, but do not exhibit other clinical phenotypes of MVA syndrome, with the exception of one BubR1-based aneuploid model (8).

This particular model was part of a series of mouse mutants with a graded reduction in BUBR1 protein levels created by the use of wild-type (+), hypomorphic (H), and knockout (−) BubR1 alleles. Mutants expressing 0% (BubR1<sup>−/−</sup>) or approximately 5% (BubR1<sup>H/H</sup>) of normal BUBR1 protein levels fail to survive beyond embryonic day 3.5 (E3.5) and postnatal day 1, respectively, but mice expressing approximately 10% BUBR1 (BubR1<sup>F<sub>1002P</sub></sup>) are viable (8). Besides near-diploid aneuploidies, these mice exhibit growth retardation, facial dysmorphisms, skeletonmuscular, renal, and cardiac anomalies, cataracts, lipodystrophy, and early mortality (8–11). Furthermore, BubR1<sup>F<sub>1002P</sub></sup> mice are sensitive to carcinogen-induced tumors, but do not live long enough to assess predisposition to spontaneous tumors (12). Several of the progeroid phenotypes in BubR1<sup>F<sub>1002P</sub></sup> mice are driven by the accumulation of senescent cells (9–11), which in
turn led to the identification of cellular senescence as a key contributor to natural aging (13).

Two additional observations have reinforced a possible role for BUBR1 in aspects of natural aging. First, BUBR1 levels decline in various tissues with chronological aging, with geriatric wild-type mice expressing similar amounts of the protein to those of young BubR1<sup>+/+</sup> mice (8). Second, transgenic mice that constitutively overexpress BUBR1 are not subject to an age-related decline in BUBR1 and have an increased lifespan with attenuations in muscle and renal atrophy, glomerulosclerosis, cardiac aging, and tumor latency (14). BUBR1 overexpression was also shown to counteract age-related aneuploidization in various tissues, raising the possibility that inaccurate chromosome segregation may be a driver of tissue deterioration with aging. BUBR1 overexpression appears to reinforce both the spindle assembly checkpoint (SAC) and the mitotic error correction machinery, which may underlie the observed reductions in aneuploidization rates (15).

The high clinical heterogeneity among MVA patients with BUBR1 mutations has prompted the idea that BUBR1 is a multi-tasking protein implicated in a wide variety of biological processes that are differently disrupted, depending on the exact nature of the mutations involved. Early in mitosis, BUBR1, together with MAD2, BUB3, and CDC20, assembles into a potent 4-subunit inhibitor (known as the mitotic checkpoint complex, MCC) of the anaphase-promoting complex (APC/C) that prevents premature anaphase and chromosome missegregation as part of the SAC (16, 17). Once each chromosome has properly and stably attached to the mitotic spindle and sufficient inter-kinetochore tension is generated, the MCC dissociates, allowing APC/C/CDC20 to mediate the proteasomal degradation of cyclin B1 and securin, thereby triggering sister chromatid separation and anaphase onset. BUBR1 also prevents chromosome missegregation as a key component of the Aurora B–driven error correction machinery, which acts to destabilize aberrant microtubule-kinetochore attachments, and through the reactivation of the SAC allows time for proper attachments to occur (18). In this context, BUBR1 localized at mitotic kinetochore microtubules acts to recruit PP2A, the phosphatase that counteracts the destabilizing activity of Aurora B kinase (19). Furthermore, BUBR1 regulates clathrin-mediated internalization of the insulin receptor by virtue of its ability to bind to both MAD2 and AP2, thereby quenching signaling through this receptor (20). BUBR1 fulfills this newly discovered function in interphase, further supporting the idea that BUBR1 is a functionally diverse protein with a plethora of mitotic and non-mitotic roles.

Despite significant progress toward understanding these contributions of BUBR1, it remains unclear what the full spectrum of physiologically relevant functions of this protein are, the extent to which the various BUBR1 mutations might perturb these functions, and how all this contributes to the vast clinical heterogeneity within MVA syndrome. To begin to address some of these unresolved questions, we sought to mimic human BUBR1 mutations in mice and characterize the phenotypic consequences. Here, our use of 4 such mutations in various combinations with each other or in combination with a BubR1<sup>+/+</sup> allele demonstrates that subtle allelic effects contribute to disease heterogeneity in both MVA patients and heterozygous carriers of MVA mutations, beyond rates of aneuploidy and BUBR1 protein levels.

### Results

**Mice modeling MVA patient BUBR1<sup>X753/L1012P</sup> die during early embryogenesis.** BUBR1 2211insGTTA, a mutant BUBR1 allele that results in a frameshift and yields an unstable truncated protein referred to as BUBR1<sup>X753</sup> has been identified in 2 biallelic MVA patients, one of which also inherits BUBR1 3035T>C, a mutant allele that encodes BUBR1<sup>X1012P</sup> (2). To model this particular patient, we used a previously established mouse strain in which we mimicked the BUBR1 2211insGTTA allele (21) and a new strain in which we converted the leucine at position 1002 to a proline (human L1012 corresponds to mouse L1002; Figure 1A and Supplemental Figure 1, A–C; supplemental material available online with this article; https://doi.org/10.1172/JCI126863DS1). As expected, heterozygotes carrying the L1002P substitution (referred to as BubR1<sup>+/L1002P</sup> mice) were overtly normal. However, mouse embryonic fibroblasts (MEFs) and tissues from BubR1<sup>+/L1002P</sup> mice contained markedly reduced BUBR1 levels (Figure 1B). Side-by-side comparisons of BubR1<sup>+/L1002P</sup>, BubR1<sup>+/+</sup>, and BubR1<sup>+</sup>/X753 MEFs and tissues implied that the BubR1<sup>+/L1002P</sup> allele overall yields very little protein (Figure 1B). However, MEFs and testes from BubR1<sup>+/+</sup> and BubR1<sup>+</sup>/X753 mice had significantly lower BUBR1 protein levels than corresponding tissues from BubR1<sup>+/L1002P</sup> mice, whereas levels were similarly low in the thymus and spleen of all 3 genotypes. The L1002P mutation had no impact on BubR1 transcript stability, but the truncating X753 mutation did, with BubR1<sup>+</sup>/X753 MEFs yielding transcript levels similar to those of BubR1<sup>+/+</sup> MEFs (Supplemental Figure 2A). Assessments of BUBR1 protein stability revealed that proteasomal degradation of BUBR1<sup>L1002P</sup> was elevated (Supplemental Figure 2, B and C), which is in concordance with an earlier study showing that human BUBR1<sup>L1002P</sup> protein is misfolded and therefore less stable (7). Nevertheless, mitotic BubR1<sup>+/L1002P</sup> MEFs were still able to accumulate normal amounts of BUBR1 at unattached kinetochores, as demonstrated by immunofluorescence (IF) labeling for BUBR1 (Supplemental Figure 2F). BUBR1 WT protein stability in BubR1<sup>+/X753</sup> MEFs seemed similar to that in BubR1<sup>+/+</sup> and BubR1<sup>+</sup>/X753 MEFs (Supplemental Figure 2, C–E).

To model the MVA patient BUBR1<sup>X753/L1012P</sup>, we intercrossed BubR1<sup>+/L1002P</sup> and BubR1<sup>+</sup>/X753 mice, but no BubR1<sup>+</sup>/X753/L1012P mice were identified among 388 newborn pups (Supplemental Table 1). This was unexpected because the patient with this genetic combination was alive for 3.6 months after birth, despite growth retardation and anomalies in a broad spectrum of tissues, including heart, lung, brain, eye, thyroid, and erythrocytes (2). To determine when BubR1<sup>+</sup>/X753/L1012P mice die during embryogenesis, we genotyped a total of 39 E13.5 mice from heterozygous intercrosses, but again no BubR1<sup>+</sup>/X753/L1012P mice were observed, whereas BubR1<sup>+/L1002P</sup>, BubR1<sup>+/X753</sup>, and BubR1<sup>+</sup>/X753 mice were present at expected frequencies (Supplemental Table 1). However, repeating the analysis at E3.5 yielded viable BubR1<sup>+</sup>/X753/L1012P embryos, which were overtly indistinguishable from their BubR1<sup>+/L1002P</sup>, BubR1<sup>+</sup>/X753, and BubR1<sup>+</sup>/counterparts (Supplemental Table 1). Attempts to culture the inner cell mass from BubR1<sup>+</sup>/X753/L1012P blastocysts were unsuccessful; however, this was indicative of early embryonic death due to mitotic failure (data not shown). Thus, a mouse model for MVA patient BUBR1<sup>X753/L1012P</sup> is unattainable, most likely due to severe mitotic defects that interfere with early embryogenesis.
Models for heterozygous BUBR1 MVA mutations show phenotypic heterogeneity. Whether heterozygous carriers of BUBR1 MVA mutations might develop any symptoms associated with the syndrome is a key question that remains to be addressed. In a previous study, we examined mice that model an MVA allele carrier, heterozygous for the BUBR1X753 mutation, and found that these mice were indeed more susceptible to cancer and select progeroid phenotypes than their wild-type counterparts (21). To develop a more comprehensive understanding of the impact of heterozygous MVA mutations, we modeled heterozygous carriers of 2 other MVA alleles, BUBR1L1012P and BUBR1X753, the latter representing the null allele found in a biallelic MVA patient that also carries a BUBR1I909T mutation (2). The necessary cohorts of BubR1+/+, BubR1+/L1002P, and BubR1+/– mice were established by intercrossing BubR1+/+L1002P and BubR1+/– mice. Consistent with earlier data (21), BubR1+/– mice had a modest, but significant, reduction in lifespan compared with BubR1+/+ mice (Figure 2A). BubR1+/L1002P mice also showed a strong trend toward reduced median lifespan that was close to reaching significance (P = 0.0516, log-rank test). Although in both heterozygous mutant cohorts the incidence and spectrum of spontaneous tumors detectable at autopsy were similar to wild-type (Figure 2, B and C), tumor latencies in both mutants were significantly reduced (Figure 2A), indicating that both MVA mutations may promote tumorigenesis by accelerating tumor growth. Consistent with this, lymphomas from BubR1+/+L1002P and BubR1+/– mice, which developed with reduced latencies, contained significantly more mitotic cells than lymphomas of BubR1+/+ mice (Figure 2, D and E). A complementary experiment in which we analyzed tumor-
Figure 2. Carriers of single BUBR1 MVA mutations are phenotypically heterogeneous. (A) Kaplan–Meier curves showing overall survival (left) and cancer deaths only (right) of the indicated mice. Values associated with curves denote median survival. (B) Incidence of cancer deaths in the indicated mice. (C) Spectrum of cancer types associated with cancer deaths in the indicated mice. (D) Kaplan–Meier curve for lymphoma deaths of the indicated mice. Median survival is indicated. (E) Mitotic index of the lymphoma tumor samples collected from the indicated moribund mice. Images of representative pHH3-labeled lymphoma sections are shown. Scale bar: 50 μm. (F and G) DMBA-induced lung tumor incidence, multiplicity, and volume in the indicated mice. Bars in E–G represent the mean ± SEM, and dots represent individual samples. Each n for all experiments represents individual mice, with the exception of tumor volume in F–G where individual tumors are represented. Statistical significance was determined using a log-rank test (A and D), 2-tailed Fisher’s exact test (B–C and F–G, incidence), 1-way ANOVA with the Holm–Šídák post hoc test (E), and a Mann–Whitney U test (F–G, tumor number and volume). *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.
BubR1 ++/X753 MEFs compared with BubR1 ++/+ MEFs (Figure 3A and Supplemental Table 2). Premature chromatid separation (PCS), a hallmark of MVA patients, was observed in all 3 MVA allele carriers (Figure 3A). We complemented these experiments with interphase fluorescence in situ hybridization (FISH) analyses for chromosomes 4 and 7 in these MEFs, which targets the entire cell population rather than only the mitotically active fraction. Aneuploidy rates were again similarly increased in all 3 MVA allele carriers (Supplemental Figure 5 and Supplemental Table 3).

By monitoring chromosome movements during mitosis in live cells expressing histone H2B–monomeric red fluorescent protein (H2B-mRFP), we observed small, but significant increases in chromosome segregation errors for all 3 heterozygous BubR1 MVA mutants (Figure 3B). In all 3 heterozygous mutants both the SAC and attachment error correction machinery were impaired, providing an explanation for the observed increase in segregation errors (Figure 3, C and D). However, both high-fidelity chromosome segregation insurance systems were similarly impaired in all 3 mutants, prompting us to screen for additional mitotic defects that might explain the higher rates of lagging chromosomes in BubR1 ++/L1002P and BubR1 ++/+ MEFs (Figure 3B). Lagging chromosomes are frequently caused by aberrancies in centrosome disjunction or movement that result in the formation of non-perpendicular spindles that are enriched in merotelic kinetochore-microtubule attachments.

To extend our cancer susceptibility studies, we challenged BubR1 ++/+ , BubR1 ++/L1002P, and BubR1 ++/+ mice with 7,12-dimethylbenz(a)anthracene (DMBA), a carcinogen that primarily induces lung tumors when applied on the dorsal skin at postnatal day 5 (22). Both BubR1 ++/L1002P and BubR1 ++/+ mice showed no increase in lung tumor incidence in this tumor bioassay. Lung tumor multiplicity and size, however, were significantly increased in BubR1 ++/+ mice, and likewise lung tumor size was also increased in BubR1 ++/L1002P mice, indicative of accelerated tumor growth and/or initiation (Figure 2, F and G).

By monitoring chromosome movements during mitosis in live cells expressing histone H2B–monomeric red fluorescent protein (H2B-mRFP), we observed small, but significant increases in chromosome segregation errors for all 3 heterozygous BubR1 MVA mutants (Figure 3B). In all 3 heterozygous mutants both the SAC and attachment error correction machinery were impaired, providing an explanation for the observed increase in segregation errors (Figure 3, C and D). However, both high-fidelity chromosome segregation insurance systems were similarly impaired in all 3 mutants, prompting us to screen for additional mitotic defects that might explain the higher rates of lagging chromosomes in BubR1 ++/L1002P and BubR1 ++/X753 MEFs (Figure 3B). Lagging chromosomes are frequently caused by aberrancies in centrosome disjunction or movement that result in the formation of non-perpendicular spindles that are enriched in merotelic kinetochore-microtubule attachments.

Heterozygous BUBR1 MVA mutants demonstrate intricate mitotic phenotypes. To examine the impact of heterozygous BUBR1 MVA mutations on chromosome number integrity, we performed chromosome counts on metaphase spreads of MEFs at passage-5. Aneuploidy was markedly elevated in BubR1 ++/L1002P, BubR1 ++/+ , and BubR1 ++/X753 MEFs compared with BubR1 ++/+ MEFs (Figure 3A and Supplemental Table 2). Premature chromatid separation (PCS), a hallmark of MVA patients, was observed in all 3 MVA allele carriers (Figure 3A). We complemented these experiments with interphase fluorescence in situ hybridization (FISH) analyses for chromosomes 4 and 7 in these MEFs, which targets the entire cell population rather than only the mitotically active fraction. Aneuploidy rates were again similarly increased in all 3 MVA allele carriers (Supplemental Figure 5 and Supplemental Table 3).
Indeed, both monoallelic MVA mutants with increased chromosome lagging formed non-perpendicular spindles at elevated rates, due to slow centrosome movement (Figure 3, E and F). Although it remains to be determined how BUBR1 impacts centrosome movement, it is clear that there is an allele-dependent effect on this process. Overall, the above experiments indicate that allelic effects beyond BUBR1 levels alone contribute to the mitotic phenotypes of monoallelic MVA mutants.

We complemented our analyses of cultured MEFs with chromosome counts on splenocytes of 5-month-old BubR1+/–, BubR1+/L1002P, and BubR1+/X753 mice. Specifically, we briefly cultured freshly harvested splenocytes in the presence of colcemid for 4 hours prior to preparing metaphase spreads and counting chromosomes. This method assesses the percentage of aneuploid cells among the subset of cycling splenocytes entering mitosis. We observed major differences in aneuploidy between heterozygous BubR1 MVA mutants, with 2%, 18%, and 28% of mitotic splenocytes showing abnormal chromosome numbers in BubR1+/–, BubR1+/X753, and BubR1+/L1002P mice, respectively (Figure 4A and Supplemental Table 4). The same was true for PCS (Figure 4A). To investigate karyotypic instability in greater depth, we conducted interphase FISH analysis for chromosomes 4 and 7 on liver, lung, and spleen of BubR1+/–, BubR1+/L1002P, and BubR1+/X753 mice ranging in age from 22–24 months. Instead of tissues, we prepared single-cell suspensions from the above tissues sections, we performed single-cell suspensions from the above tissues and dropped these on slides to avoid the loss of nuclear content that occurs with sectioning (14). Our analyses showed that aneuploidy was increased in livers of BubR1+/L1002P and BubR1+/– mice, as well as in lungs of BubR1+/L1002P and BubR1+/X753 mice (Figure 4B and Supplemental Table 3). Aneuploidy rates in the spleen, as measured by FISH, were not elevated in any of the monoallelic MVA mutants, even though substantial increases were observed in mitotically active splenocytes of these strains (Figure 4, A and B). One possible explanation might be that chromosome missegregation or aneuploid cell survival rates differentially change over time for each of the mutants. Notwithstanding these differences, collectively, these data suggest that a key feature of MVA syndrome patients, increased aneuploidy in multiple tissues, is conserved in heterozygous carriers of BUBR1 MVA mutations.

Progeroid BubR1+/X753 mice exhibit hyperactive mTORC1 signaling. To further investigate the basis for the phenotypic heterogeneity among monoallelic MVA mutants, we conducted genome-wide transcriptome profiling on gastrocnemius muscle from 3-month-old BubR1+/X753, BubR1+/L1002P, and BubR1+/+ mice. This tissue was chosen because in BubR1+X753 mice it is selectively subject to accelerated aging (21). The 3-month time point was selected because at this age no signs of muscle aging are detected, allowing for detection of primary alterations resulting from the presence of the BubR1X753 allele rather than secondary transcriptional changes associated with sarcopenia. Strikingly, several hundred differentially expressed genes (DEGs) emerged when comparing BubR1+/X753 with BubR1+/+, whereas the transcriptome of BubR1+/L1002P skeletal muscle was similar to that of BubR1+/+, yielding only 3 DEGs (Figure 5A). Comparison of BubR1+/X753 with BubR1+/L1002P also yielded a significant number of DEGs, albeit fewer than compared with BubR1+/+ (Figure 5A). Functional enrichment analyses with the DEGs using the STRING database (25) revealed that the majority of cellular functions that were significantly enriched in the upregulated DEGs of BubR1+/X753 skeletal muscle were linked to the mTORC1 signaling pathway (Figure 5B), which has been linked to aging (26). In addition, a high percentage of the upregulated DEGs from the BubR1+/X753 versus BubR1+/L1002P comparison function in mTORC1-related biological processes (Supplemental Figure 6, A and B). Consistent with this, phosphorylation of 2 key mTORC1 substrates, p70 S6 kinase and 4EBP1, were markedly increased in skeletal muscle of 3-month-
old BubR1+/X753 mice compared with corresponding lysates from BubR1+/L1002P and BubR1+/+ mice, as determined by Western blot analysis (Figure 5C). Skeletal muscle from BubR1+/L1002P and BubR1+/X753 mice had similarly reduced BUBR1 protein levels compared with BubR1+/+ mice, indicating that differences in BUBR1 protein levels are unlikely to account for the differential impact of these MVA mutations on mTORC1 signaling (Figure 5D). The possibility that BUBR1 levels initially decline similarly in BubR1+/L1002P and BubR1+/X753 young adult mouse tissues, but then more rapidly in BubR1+/X753 mice as animals reach a more advanced age is also unlikely, as suggested by Western blot analysis for BUBR1 on spleen lysates of 24-month-old mice (Supplemental Figure 7).

BubR1+/L1002P mice are viable and model MVA syndrome-associated pathologies. Following our unsuccessful attempt to model the BUBR1+/L1002P MVA patient in mice, we asked whether the BubR1H allele, which mimics the hypomorphic allele found in patients with monoallelic BUBR1 mutations (1, 8), might produce viable offspring when combined with BubR1X753 or BubR1L1002P. Indeed, intercrosses of BubR1+/X753 and BubR1+/H mice yielded viable BubR1+/+/X753 offspring; however, these mice failed to thrive and died within 18 hours after birth (Figure 6A), reminiscent of BubR1+/H mice (8). Comparative Western blot analysis of MEF lysates revealed that BubR1+/H and BubR1+/X753 MEFs had a similar reduction in BUBR1 protein (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B). On the other hand, intercrosses of BubR1+/L1002P and BubR1+/H mice yielded BubR1+/L1002P mice that had a normal appearance at birth, but became growth retarded during postnatal development, although not as severely as BubR1+/H mice (Figure 6B).
Figure 6. Mouse models carrying 2 allelic BubR1 MVA patient variants are viable. (A) Image of BubR1+/+ and BubR1H/L1002P pups a few hours after birth. (B) Western blots of asynchronous passage-5 MEF lysates, probed for BUBR1. PonS-stained proteins served as the loading control. Three independent lines were used for analyses. BUBR1 levels were quantified and are shown as in Figure 1B. (C) Representative image of 8- to 10-month-old mice. Dashed yellow line outlines curvature of the spine, indicating kyphosis phenotype in BubR1H/L1002P and BubR1H/H mice. (D) Mean weights of BubR1+/+, BubR1H/L1002P, and BubR1H/H mice at 5-7 months of age. Each n indicates independent mice. (E) Western blots of tissues from 6-week-old (testes, thymus, and spleen) and 10-day-old (gastrocnemius muscle and fat) mice, and passage-5 asynchronous MEFs of the indicated genotypes. PonS served as the loading control. BUBR1 levels were quantified and are shown as in Figure 1B. (F) Survival curves for the indicated mouse models. Values associated with curves denote median survival. *P < 0.05 for BubR1H/H versus BubR1H/L1002P. (G) DMBA-induced lung tumor incidence, multiplicity, and volume in the indicated mice. Data in D and G are presented as the mean ± SEM, and dots represent individual samples. Statistical significance was determined using 1-way ANOVA with the Holm–Šídák post hoc test (B, D, and E), log-rank test (F), 2-tailed Fisher’s exact test (G, incidence), and Mann–Whitney U test (D and G, tumor number and volume). *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant.
multiplicity of DMBA-induced lung tumors were significantly elevated (Figure 6G), analogous to \( \text{BubR}1^{+/+} \) mice (12). However, the average lung tumor size was increased in DMBA-treated \( \text{BubR}1^{+/-} \) mice compared with corresponding \( \text{BubR}1^{+/+} \) mice (Figure 6G). This was not observed in \( \text{BubR}1^{+/+} \) mice (12) and is perhaps a feature of select MVA alleles, as this was also noted in a milder form in \( \text{BubR}1^{+/-} \), \( \text{BubR}1^{-/-} \), and \( \text{BubR}1^{+/-X753} \) mice (Figure 2, F and G, and ref. 21).

differences observed only in the spleen (Figure 6E). \( \text{BubR}1^{+/+} \) mice had a median lifespan of 343 days compared with 691 days for \( \text{BubR}1^{+/+} \) mice (Figure 6F). Although \( \text{BubR}1^{+/+} \) mice were short-lived, on average they lived significantly longer than \( \text{BubR}1^{+/+} \) mice, which had a median lifespan of 196 days (Figure 6F).

Similar to \( \text{BubR}1^{+/+} \) mice, \( \text{BubR}1^{+/+} \) mice were not prone to spontaneous tumors, with only 13% of mice dying with macroscopically detectable tumors. Furthermore, the incidence and

Figure 7. \( \text{BubR}1^{+/+} \) and \( \text{BubR}1^{+/+} \) mice recapitulate MVA syndrome heterogeneity. (A) Kaplan-Meier curves of cataract onset in the indicated mice. Values associated with curves denote median onset. Representative images of 5-month-old mice are shown in insets. (B) Kaplan-Meier curves of kyphosis onset in the indicated mice. Values associated with curves denote median onset. \( P < 0.001 \) for \( \text{BubR}1^{+/+} \) versus \( \text{BubR}1^{+/+} \). (C) Analysis of forelimb grip strength in the indicated mice. (D) Histological analyses of gastrocnemius and measurement of muscle fiber cross-sectional area in the indicated 8- to 10-month-old mice. Representative images shown. Scale bar: 50 \( \mu \)m. (E) Mean work output, in joules (J), during a treadmill exercise test of 5- to 7-month-old mice. (F) Mean total body fat percentage of 8- to 10-month-old mice, as determined by echo-MRI analyses. (G) Histological analyses of inguinal adipose tissue (IAT) and measurement of adipocyte cross-sectional area in the indicated 8- to 10-month-old mice. Representative images shown. Scale bar: 50 \( \mu \)m. (H) Survival curves of the indicated 4- to 7-month-old mice exposed to a low-dose isoproterenol regimen to evaluate cardiac stress tolerance. Each \( n \) indicates independent mice for all experiments. Data in C–G are presented as mean ± SEM, and dots represent individual samples. Statistical significance was determined using a log-rank test (A, B, and H) and 1-way ANOVA with the Holm-Šidák post hoc test (C–G). * \( P < 0.05 \); ** \( P < 0.01 \); *** \( P < 0.001 \). NS, not significant.
BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> mice model MVA syndrome heterogeneity. We sought to further explore the extent to which BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> mice are subject to phenotypic heterogeneity, a hallmark of MVA syndrome. To this end, we focused on a series of progeroid phenotypes that characterize BubR1<sup>H/H</sup> mice, most of which represent MVA-associated pathologies. We discovered that BubR1<sup>H/L1002P</sup> mice are highly sensitive to cataract formation, the median onset of which was 161 days, which is nearly identical to that of BubR1<sup>H/H</sup> mice (median onset, 168 days; Figure 7A).

A second overt progeroid phenotype of BubR1<sup>H/H</sup> mice, kyphosis, also developed in BubR1<sup>H/L1002P</sup> mice, but with delayed latency compared with BubR1<sup>H/H</sup> mice (median onset, 238 days versus 175 days; Figure 7B). In BubR1<sup>H/H</sup> mice, this phenotype is linked to a number of features of sarcopenia, including reduced grip strength, muscle fiber atrophy, and reduced work output during treadmill exercise (Figure 7, C–E, and Supplemental Figure 8, B and C). Importantly, these same features were observed in BubR1<sup>H/L1002P</sup> mice, although typically they were less severe in BubR1<sup>H/L1002P</sup> mice compared with BubR1<sup>H/H</sup> mice, which is in accordance with the delay in kyphosis onset.

Another key progeroid phenotype of BubR1<sup>H/H</sup> mice is fat tissue atrophy (lipodystrophy). Echo-MRI analysis on 8- to 10-month-old mice indicated that this phenotype was fully recapitulated in BubR1<sup>H/L1002P</sup> mice (Figure 7F), which we confirmed by subsequent weighing of individual subcutaneous and visceral fat depots (Supplemental Figure 8D). Furthermore, the average size of fat cells was markedly reduced in BubR1<sup>H/L1002P</sup> mice compared with BubR1<sup>H/H</sup> mice, which is in accordance with the delay in kyphosis onset.

Loss of cardiac stress tolerance is a hallmark of aging and has previously been linked to decreasing BUBR1 levels with aging (14). In accordance with this, cardiac stress tolerance of BubR1<sup>H/H</sup> mice is very low and is thought to be the primary cause of premature death in this model. To determine whether cardiac stress tolerance might be reduced in BubR1<sup>H/L1002P</sup> mice, and if so, whether the magnitude of the decline might correlate with the extent of lifespan shortening, we performed an isoproterenol challenge test. In this assay, which does not impact survival of BubR1<sup>H+/+</sup> mice, we intraperitoneally injected a low dose of the β-adrenergic drug isoproterenol twice a day for 4 weeks (15). As expected, BubR1<sup>H/H</sup> mice were highly sensitive to repeated isoproterenol administration, with half of the animals dying within 5 injections (Figure 7H). Lethality was also observed in BubR1<sup>H/L1002P</sup> mice, but to a lesser extent, as 50% of the animals expired after 18 injections and some of the remaining mice showed no overt susceptibility. These data strengthen the idea that reduced tolerance to cardiac stress is a key determinant of lifespan shortening in biallelic BubR1 MVA syndrome models. Collectively, these data indicate that phenotypic heterogeneity occurs despite similarity in overall BUBR1 protein level and that some phenotypes are more prone to divergency than others.

Progeroid heterogeneity occurs despite mitotic phenotype similarity. The random reshuffling of chromosomes in multiple tissues is a common feature of MVA syndrome patients, irrespective of whether they have mutations in BUBR1, CEP57, or TRIP13 (1–4). However, whether and how the clinical heterogeneity that characterizes MVA syndrome might be driven by heterogeneity of mitotic defects has been difficult to assess, primarily because of the rarity of the syndrome and the limited availability of patient samples. Although attempts to model MVA patient mutations in mice have proven difficult (Supplemental Table 1 and ref. 6), a systematic analysis of the mitotic phenotypes of the currently available models is likely to provide valuable insight into the extent to which mitosis-related abnormalities might contribute to the pathological heterogeneity. To do so, we subjected BubR1<sup>H/X753</sup>, BubR1<sup>H/L1002P</sup>, and BubR1<sup>H/H</sup> MEFs and multiple tissues from BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> adult mice to the same mitotic and karyotypic tests that we conducted on mice modeling heterozygous BUBR1 MVA mutations (Figures 3 and 4).

We detected exceptionally high rates of both aneuploidy and PCS in passage-5 BubR1<sup>H/X753</sup> MEFs (Figure 8A and Supplemental Table 2), similar to earlier data on BubR1<sup>H/H</sup> MEFs (65% versus 72% aneuploidy, respectively) (8). This is in accordance with the fact that BubR1<sup>H/X753</sup> and BubR1<sup>H/H</sup> mice both die shortly after birth and express similar BUBR1 levels in MEFs (Figure 6, A and B). Aneuploidy rates were also relatively high in BubR1<sup>H/L1002P</sup> MEFs, reaching virtually the same levels as observed in BubR1<sup>H/H</sup> MEFs (Figure 8A and Supplemental Table 2). The only notable difference between the 2 genotypes was the dramatic difference in PCS (Figure 8A), indicating that the presence of BUBR1<sup>H/L1002P</sup> protein interferes with the cell’s ability to sustain strong bonds between duplicated chromosomes before anaphase onset. To examine the aneuploidy phenotypes of these biallelic MVA mutants in greater depth, we performed single-cell DNA sequencing on asynchronously growing passage-5 BubR1<sup>H/X753</sup> MEFs not only had the highest aneuploidy incidence, but also much more complex aneuploidy than BubR1<sup>H/H</sup> MEFs (Figure 8H), as was BUBR1 accumulation at unusually late mitotic stages in BubR1<sup>H/X753</sup> MEFs (65% versus 10% in BubR1<sup>H/H</sup> MEFs (Figure 8B). In all 3 mutants, most aneuploidy resulted from chromosome gains (Figure 8, C and D). BubR1<sup>H/X753</sup> MEFs not only had the highest aneuploidy incidence, but also much more complex aneuploidy than BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> MEFs, as evidenced by the increased number of chromosomes impacted per cell (Figure 8, E and F, and Supplemental Figure 9C). Furthermore, in all 3 mutants, numerical changes occurred across a broad spectrum of chromosomes with little repetition (Supplemental Figure 9, A and B). Only BubR1<sup>H/X753</sup> MEFs had a few chromosomes that were more frequently gained, including chromosomes 2, 6, 8, and 10 (Supplemental Figure 9A). Chromosome losses were infrequent in BubR1<sup>H/H</sup> MEFs compared with BubR1<sup>H/X753</sup> and BubR1<sup>H/L1002P</sup> MEFs (Supplemental Figure 9B). No increases in structural or segmental aneuploidy were observed in any of the biallelic MVA mutant MEFs compared to BubR1<sup>H+/+</sup> MEFs (Supplemental Figure 9, D and E). Collectively, these data indicate that early postnatal lethality, as observed in BubR1<sup>H/X753</sup> mice, does seem to correlate with increases in both the rate and complexity of aneuploidization.

Consistent with the similarity in aneuploidy phenotypes, BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> MEFs had the same chromosome missegregation rates, even though the prevalence of the actual types of segregation errors differed to some extent (Figure 8G). SAC activity was severely compromised in both BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> MEFs (Figure 8H), as was BUBR1 accumulation at unattached kinetochores at the onset of mitosis (Supplemental Figure 10, A and B). Similar to the high increase in aneuploidy observed in BubR1<sup>H/X753</sup> MEFs, these cells also exhibited significantly higher rates of chromosome missegregation compared with BubR1<sup>H/L1002P</sup> and
likely driven by a combination of defects, including reduced SAC activity, defective attachment error correction, and aberrations in centrosome movement and spindle symmetry, with the higher level of aneuploidy in BubR1H/X753 MEFs probably due to more defective attachment error correction machinery.

Aneuploidy rates in mitotic splenocytes from 5-month-old BubR1H/L1002P and BubR1H/H mice were also markedly elevated, but unlike MEFs, to different degrees (38% and 15%, respectively) (Figure 9A, Supplemental Table 4, and ref. 8). The same was true for rates of PCS (Figure 9A). FISH analysis for chromosomes 4 and 7 showed that rates of karyotypic abnormalities were prominently increased in a broad spectrum of tissues from both BubR1H/L1002P and BubR1H/H mice, with minimal differences observed between the 2 genotypes (Figure 9B and Supplemental Table 3). However, since BubR1H/H MEFs also exhibited a significant increase in chromatin bridges, we assessed DNA damage by performing IF for the double-strand break (DSB) protein, 53BP1. However, we did not observe a significant increase in DSBs in any of the mutants (Figure 8L). Thus, chromosome missegregation in biallelic MVA mutants is likely driven by a combination of defects, including reduced SAC activity, defective attachment error correction, and aberrations in centrosome movement and spindle symmetry, with the higher level of aneuploidy in BubR1H/X753 MEFs probably due to more defective attachment error correction machinery.

Aneuploidy rates in mitotic splenocytes from 5-month-old BubR1H/L1002P and BubR1H/H mice were also markedly elevated, but unlike MEFs, to different degrees (38% and 15%, respectively) (Figure 9A, Supplemental Table 4, and ref. 8). The same was true for rates of PCS (Figure 9A). FISH analysis for chromosomes 4 and 7 showed that rates of karyotypic abnormalities were prominently increased in a broad spectrum of tissues from both BubR1H/L1002P and BubR1H/H mice, with minimal differences observed between the 2 genotypes (Figure 9B and Supplemental Table 3). However,
aneuploidy rate or degree alone does not clearly correlate with the severity of the progeroid phenotypes observed in BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> MVA models, implying that other pathological events are key contributors or drivers.

**Senescence-driven progeroid mechanisms are conserved in MVA models.** Cellular senescence contributes to the development of certain progeroid phenotypes in BubR1<sup>H/H</sup> mice, including sarcopenia, lipodystrophy, and cataract formation (9, 10). Although the senescence-inducing stressors in this model remain elusive, aneuploidy alone does not seem to be sufficient to activate this cell fate program. This is largely based on the observation that several CIN models involving genes other than BubR1 are not senescence prone, despite similar or higher rates of aneuploidization than reported for the BubR1<sup>H/H</sup> model (27). However, 2 recent studies have suggested that aneuploidy can drive senescence, at least in vitro (28, 29). In one of these studies, loss of SMC1, a component of the mitotic cohesin complex, was associated with induction of both cellular senescence and PCS, but no perturbations in SMC1 were detected in senescence-prone BubR1<sup>H/H</sup> MEFs (Supplemental Figure 10C). However, in addition to the rate of aneuploidization, the possibility that karyotype complexity is an important determining factor in cell fate determination in the various CIN models cannot be excluded and requires additional studies.

To further delineate the role of senescence in MVA syndrome pathologies, we sought to determine whether senescence also drives progeria in BubR1<sup>H/L1002P</sup> mice. Indeed, subcutaneous and visceral fat depots of BubR1<sup>H/L1002P</sup> mice stained for senescence-associated β-galactosidase (SA-β-gal) exhibited increased activity, similar to BubR1<sup>H/H</sup> mice (Figure 10A, and data not shown). To obtain further evidence for accumulation of senescent cells in BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> fat tissue, we conducted an unbiased screen for senescence markers and components comprising the senescence-associated secretory phenotype (SASP) using a transcriptomics approach. To this end, RNA was collected from inguinal adipose tissue (IAT) from 8- to 10-month-old BubR1<sup>H/H</sup>, BubR1<sup>H/L1002P</sup>, and BubR1<sup>+/+</sup> mice, and was used for RNA sequencing. Although BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> IAT had several thousand DEGs when compared with IAT of BubR1<sup>+/+</sup> mice, only 16 DEGs were observed when BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> transcriptomes were compared to each other (Figure 10B), indicating that similar biological aberrations occur in fat tissue of the 2 MVA models. Further, evaluation of the expression of the Cdkn2a locus, a well-established marker of cellular senescence and key driver of senescence in BubR1<sup>H/H</sup> mice (9, 10), revealed similarly elevated levels in both BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> fat tissue (Figure 10B). To further evaluate the senescent-cell signature in these 2 models, we interrogated our lists of upregulated DEGs for putative SASP factors by evaluating the presence of genes encoding extracellular proteins (30). One hundred ninety of the DEGs observed in the IAT between MVA models and wild-type mice encode extracellular proteins, many of which comprised known SASP functions, including proinflammatory factors, growth factors, regulators of extracellular protease activity, and other signaling factors (Figure 10C), supporting the idea that senescent cells with a bioactive secretome accumulate in fat tissue of MVA models. Next, we focused on senescence in skeletal muscle. In contrast with fat,
**Figure 10.** Senescence-mediated pathologies are conserved among MVA models. (A) Images of SA-β-gal activity in adipose tissue (perirenal and IAT) from the indicated 8- to 10-month-old mice. (B) Venn diagrams of significantly DEGs from RNA sequencing analyses of 8- to 10-month-old fat (IAT) from the indicated mice (left), upregulated genes; ↓, downregulated genes. Heatmap of expression (row Z-scores) of cell cycle inhibitors p16/p19 (Cdkn2a) in each of the individual samples (right). n = 4 independent mice/genotype were used for analyses. FC, fold change. (C) Venn diagrams of putative SASP factors within the upregulated DEGs from BubR1H/L1002P versus BubR1H/H and BubR1H/L1002P versus BubR1H/H RNA sequencing results from fat, determined by overlap with a gene ontology (GO) GO:0005615 “Extracellular Space” gene list (top). Heatmap of expression of 53 select putative SASP factors significantly upregulated in BubR1H/L1002P and/or BubR1H/H fat (bottom). Gene names in bold text denote established SASP factors. Arrowheads indicate putative SASP factors present in fat and skeletal muscle. (D) Venn diagrams of significantly DEGs from RNA sequencing analyses of 8- to 10-month-old gastrocnemius skeletal muscle from the indicated mice (left), as above in B. Heatmap of expression (row Z-scores) of cell cycle inhibitors p16/p19 (Cdkn2a) in each of the individual samples (right), as above in B, n = 4 BubR1H/H and BubR1H/L1002P, and n = 3 BubR1H/H mice were used for analyses. (E) Venn diagrams of putative SASP factors within the upregulated DEGs from BubR1H/L1002P versus BubR1H/H and BubR1H/L1002P versus BubR1H/H RNA sequencing results from skeletal muscle, as above in C (top). Heatmap of expression of 26 select putative SASP factors significantly upregulated in BubR1H/L1002P and/or BubR1H/H skeletal muscle, as above in C (bottom). See Methods for statistical analyses for RNA sequencing (B and D). **P < 0.01; ***P < 0.001. NS, not significant.

**BubR1H/H** and **BubR1H/L1002P** gastrocnemius had only a few hundred DEGs compared with wild-type, and a higher percentage of DEGs was identified between the 2 mutants (Figure 10D). However, in accordance with increased senescence, Cdkn2a expression was also significantly increased in both mutants (Figure 10D), and a substantial proportion of the upregulated DEGs also encoded putative SASP factors (Figure 10E). Although there was some overlap between putative SASP factors of BubR1H/L1002P and
BubR1<sup>H/H</sup> muscles, BubR1<sup>H/L1002P</sup> muscles contained a relatively large number of unique SASP factors, consistent with a more severe degenerative phenotype (Figure 10E). Taken together, these findings indicate that progeroid mechanisms in select BubR1<sup>H/H</sup> tissues are mediated by the accumulation of senescent cells, which is preserved in BubR1<sup>H/L1002P</sup> mice. Furthermore, diversity in senescent cell properties (SASP composition) may underlie the difference in the severity of the progeroid skeletal muscle phenotypes between BubR1<sup>H/L1002P</sup> and BubR1<sup>H/H</sup> mice.

**Discussion**

Studies of rare genetic diseases are important in that they often provide entry points for understanding cellular and organismal mechanisms that underlie more common degenerative and pathological processes, including cancer, aging, and age-related diseases (31). To learn more about the mechanisms underlying MVA syndrome and its phenotypic heterogeneity, we sought to mimic human BUBR1 MVA mutations in mice and characterize the phenotypic consequences (summarized in Supplemental Table 5). Here, our use of 4 such mutations in various combinations, with each other or in combination with a BubR1<sup>+</sup> allele, unearthed several important insights into BUBR1 and its role in MVA progeria syndrome, including a better understanding of how the BUBR1 allelic effects drive pathological heterogeneity among patients.

First, our study uncovers that it is difficult to create mouse models for BUBR1 MVA syndrome patients. We show that a combination of BUBR1 mutations that is compatible with postnatal viability in humans causes death during early embryogenesis in mice, most likely due to mitotic failure around the time of embryo implantation, reminiscent of mice lacking the BUBR1 binding partner BUB3 (22). A recent effort to model an MVA patient with a biallelic nonsense mutation in CEPS7 supports the notion that the tolerance for MVA-associated mutations is lower in mice than in humans (6). It should be noted, however, that the BUBR1 MVA patient that our mouse model mimicked was very short-lived and died at 3.6 months of age with a broad spectrum of pathologies (2), whereas the patient that our mouse model mimicked was very short-lived and died at 3.6 months of age with a broad spectrum of pathologies (2), suggesting that hyperactive mTORC1 signaling may be a driver of accelerated sarcopenia in BubR1<sup>H/H</sup> mice. BUBR1 and MAD2 have been recently implicated in the control of insulin signaling and metabolic homeostasis, raising the interesting possibility that disruption of this function is linked to uncontrolled mTORC1 activity (20). Collectively, these data reveal that a key feature of MVA syndrome patients, phenotypic heterogeneity, is conserved among mouse models for heterozygous BUBR1 MVA allele carriers (Supplemental Table 5).

Third, although we failed to model the MVA patient BUBR1<sup>H/L1002P/X753</sup>, we successfully created a viable MVA syndrome model using BUBR1 mutations found in MVA patients. Previously, modeling was restricted to the use of hypomorphic BubR1<sup>+</sup> alleles, mimicking a BUBR1 variant found in Asian MVA patients that have no discernable mutations, but nevertheless yield low amounts of wild-type BUBR1 protein (1). However, only 1 BUBR1 MVA patient with 2 hypomorphic alleles has been reported to date (35). Although this has raised questions about the faithfulness of the model, its usefulness became more accepted with the discovery that the critical contribution of many missense mutations found in MVA syndrome patients is destabilization of the BUBR1 protein and lowering overall protein amounts (7). On the other hand, an independently generated hypomorphic model, referred to as BubR1<sup>+/−</sup>, did not show any of the overtly detectable progeroid features of BubR1<sup>H/H</sup> mice, such as kyphosis, lipodystrophy, and cataract formation (36), suggesting that subtle allelic effects may have dramatic phenotypic consequences. This idea is underscored here by the observation that BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> mice have quite obvious phenotypic differences despite an inability to detect differences in overall BUBR1 protein levels in a broad spectrum of tissues. The mere difference between total BUBR1 protein levels in BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> mice is that in the latter strain the total pool consists of a mixture of BUBR1<sup>WT</sup> and BUBR1<sup>L1002P</sup> protein rather than BUBR1<sup>WT</sup> alone. Although several phenotypes of BubR1<sup>H/L1002P</sup> are similar in severity to those of BubR1<sup>H/H</sup> mice, including lipodystrophy, cataractogenesis, and carcinogen-induced tumor susceptibility, others are definitely milder, including growth retardation, cardiac stress sensitivity, lifespan shortening, and muscle wasting. These findings are important in that they reveal that seemingly subtle allelic effects can be the cause of rather remarkable phenotypic heterogeneity, a key hallmark of MVA syndrome (Supplemental Table 5).
Fourth, although our study does not fully resolve key long-standing questions as to how changes in BUBR1 drive a broad spectrum of highly complex pathologies, it does provide several important mechanistic insights. For instance, although BUBR1 levels do not closely track with phenotypic severity, this study identifies several critical BUBR1 thresholds in vivo. A reduction of approximately 40%-90% in BUBR1 protein levels results in tumor predisposition or mild premature-aging phenotypes, whereas a reduction of greater than 90% results in progeroid phenotypes or early postnatal lethality (Supplemental Table 5). The BubR1<sup>H/H</sup>L1002P model does not fit this scheme, however, and suggests that there are other factors driving early embryonic lethality in this case, such as extensive aneuploidization. Since aneuploidy rates also increase as these critical BUBR1 thresholds are breached, it is difficult to rule this out as a contributing factor. However, it is unlikely that differences in aneuploidization represent a major source of phenotypic heterogeneity between the BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> models given that their mitotic phenotypes show remarkable similarity with regard to levels of SAC, error correction, and spindle geometry impairment, rates of chromosome missegregation, and aneuploidization in MEFs. Moreover, although aneuploidy rates in mitotically active splenocytes are substantially higher in the BubR1<sup>H/L1002P</sup> model, FISH-based assessments point to similar amounts of chromosome mosaicism in a wide spectrum of tissues of both BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> mice. Importantly, a recent study illustrated that chromosome segregation fidelity outside the normal tissue architecture is severely compromised, and that in vitro culture of cells on monolayers promotes aneuploidization (37). In light of these findings, aneuploidy data from cultured MEFs are unlikely to reflect in vivo aneuploidy rates. However, our method for assessment of aneuploidy in splenocytes is not subject to this caveat, as it does not involve any cells engaging in chromosome segregation while in culture. Since this method focuses only on a subset of splenocytes, namely those that are mitotically active, rates obtained are unlikely to faithfully reflect aneuploidy rates in the spleen at large. Therefore, the rates of aneuploidy obtained by FISH probably represent the most reliable relative measure for aneuploidy between the 2 MVA models. Moreover, FISH has been shown to be consistent with assessments of aneuploidy by whole-genome sequencing, underscoring its validity as a measure of aneuploidy (38). Another indication that aneuploidy alone is not a prominent source for phenotypic heterogeneity is that the progeroid phenotypes associated with BubR1 mutations are typically not observed in the now large collection of mouse strains with mutations in other key mitotic regulators (27, 39, 40). This even includes mutants involving prominent binding partners or closely related BUBR1 family members, such as BUB3, BUB1, MAD2, and CDC20.

Cellular senescence is one mechanism that has been causally linked to the induction of a subset of progeroid phenotypes in BubR1<sup>H/H</sup> mice, including sarcopenia, cataracts, and lipodystrophy (8, 10), but how BUBR1 aberration induces cellular senescence remains to be determined. However, our side-by-side comparison of the BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> models provides important information regarding the relationship between BUBR1 and cellular senescence. First, we demonstrate that there is a strong conservation of senescence-dependent phenotypes between the 2 independent models. Over recent years, it has become increasingly clear that the bioactive secretome of senescent cells is an important driver of tissue degeneration, but a comprehensive assessment of the SASP in the context of MVA syndrome has not been conducted. Here, using an RNA sequencing approach, we identified a broad spectrum of putative SASP factors implicated in senescent cell–dependent degeneration in fat and skeletal muscle. These findings suggest that there is substantially more heterogeneity in bioactive secretomes in vivo than expected based on initial in vitro data (41). Further, we uncovered that the number of putative SASP factors is different in fat and skeletal muscle irrespective of the MVA syndrome–causing BubR1 alleles, with fat from both BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> mice showing a rather large number of factors compared with muscle. Importantly, rates of senescence are similar between BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> mice based on levels of Cdkn2a expression. This holds true for both fat and skeletal muscle. For fat this is perhaps not surprising because lipodystrophy severity is similar between BubR1<sup>H/H</sup> and BubR1<sup>H/L1002P</sup> mice, and their SASP factors are highly conserved. In the case of skeletal muscle, however, BubR1<sup>H/H</sup> mice exhibit more severe tissue wasting than BubR1<sup>H/L1002P</sup> mice. Because BubR1<sup>H/H</sup> muscles seem to have a more complex secretome than their BubR1<sup>H/L1002P</sup> counterparts, one plausible explanation would be that senescent cells that accumulate in BubR1<sup>H/H</sup> muscles have more profound degenerative properties. This may be due to differences in senescence-inducing stressors in these mice due to allelic effects, or differential evolution of cells once they enter the senescent state, as previously suggested (42). However, the possibility that degenerative mechanisms beyond senescence may also contribute to the muscle pathology in BubR1<sup>H/H</sup> mice cannot be excluded.

In conclusion, the use of mice mimicking BUBR1 MVA mutations has unearthed many insights regarding the physiological relevance of BUBR1, and its role in MVA progeria syndrome. The results of our study predict that future modeling of other MVA mutations is likely to uncover important new clues about BUBR1-mediated biological processes in cancer, aging, and age-related diseases. Additionally, it will be imperative to establish mutant mouse models designed to identify the senescence-inducing stressors activated by BUBR1 dysfunction. Likewise, it will be important to establish mouse models that further probe the in vivo relevance of the recently discovered non-mitotic BUBR1 functions in receptor signaling, and control of CDC20-activated APC/C substrate stability (20, 43, 44).

**Methods**

**Mouse strains.** BubR1<sup>+/L1002P</sup> mice were generated by converting the first thymidine of BubR1 codon 1002 into a cytosine (CTT>CCT) using previously described gene targeting in mouse embryonic stem (ES) cells (21). See the Supplemental Figure 1 legend for details. The BubR1<sup>+/X753</sup>, BubR1<sup>+/–</sup>, and BubR1<sup>+/+</sup> mice used herein have been previously described (8, 21). All mice used in this study were on a mixed 129/Sv × C57BL/6 background, and were housed in a pathogen-free barrier facility.

**MEF generation and culture.** MEFs were generated as previously described (22). Primary MEFs were cultured and frozen at passages 2 and 3, and vials thawed and used for experiments between passages 4 and 6. At least 3 independent MEF lines were used for each experiment, unless otherwise noted.
Western blotting and quantifications. Western blot analyses were performed as previously described (8). MEF and tissue lysates were prepared as previously described (14). For assessments of BUBR1 stability, passage-5 MEFs were treated with cycloheximide, MG132, or the combination for 5 hours, as previously described (7). The mouse anti-BUBR1 (BD Transduction, catalog 612503), rabbit anti-α-tubulin (Cell Signaling Technology, catalog 2125), rabbit anti-phospho-p70 S6 kinase (Thr389; Cell Signaling Technology, catalog 9208), and rabbit anti-phospho-4E-BP1 (Thr37/46; Cell Signaling Technology, catalog 2855) primary antibodies were used at a dilution of 1:1,000. Ponceau staining (1.1 g/mL Ponceau S Sigma-Aldrich) in 1% glacial acetic acid served as a loading control unless otherwise noted. BUBR1 levels were quantified using ImageJ software (NIH) and were normalized to levels of α-tubulin or total protein using Ponceau S.

Quantitative reverse transcriptase PCR. Total RNA was extracted from passage-5 MEFs using the RNeasy mini kit (Qiagen, catalog 74104). cDNA synthesis and qRT-PCR were performed as previously described (45). See the Supplemental Figure 2 legend for details.

Karyotyping and interphase FISH. Chromosome counts of metaphase spreads from MEFs and mouse splenocytes were performed at passage-5 and 5 months of age, respectively, as previously described (22). Fifty spreads were analyzed per sample. Interphase FISH using probes for mouse chromosomes 4E2q2 and 7qA1 were performed on single-cell suspensions generated from MEFs and various mouse tissues as previously described (14). One hundred interphase cells were analyzed per sample. Karyotype analysis by single-cell DNA sequencing was performed on passage-5 MEFs as previously described (46, 47). At least 3 independent MEF lines were sequenced per genotype, and 19–24 cells were sequenced per line. Whole chromosomal and structural aneuploidies were determined using AneuFinder software (46).

IF and mitotic assays. Indirect IF was performed and quantified using ImageJ software as previously described (45). Assessments of BUBR1 (BD Transduction, catalog 612503) and SMC1 (Abcam, catalog ab133643) centromere localization (Antibodies, Inc., catalog 15-234-001) (15); centrosome movement (anti-γ-tubulin; Sigma-Aldrich, catalog T5192 and T9026) and spindle geometry (anti-γ-tubulin and -phospho-histone H3 [Ser10; pHH3]; Sigma-Aldrich, catalog T6557 and EMD Millipore, catalog 06-570) (45); and DNA damage (anti-33BP1, Novus Biologicals, catalog NB100-305) (48) were performed as previously described. A laser-scanning microscope (LSM 880; Carl Zeiss) with an inverted microscope (Axiovert 100M; Carl Zeiss) was used for imaging. The monastral washout assay was performed as previously described (15). Briefly, 100 μM monastrol (Enzo Life Sciences, catalog BML-GR322) was added to passage-5 MEFs for 60 minutes, followed by the addition of 10 μM MG132 (Sigma-Aldrich, catalog C2211) plus monastrol for an additional 60 minutes. Cells were then released in 10 μM MG132 alone for 90 minutes and fixed in 4% paraformaldehyde for 10 minutes and stained with Hoechst. Metaphase cells with 1 or more misaligned chromosomes were scored as containing uncorrected misalignments. At least 3 independent MEF lines per genotype were used for analyses, and at least 25 metaphase cells were analyzed per line.

Live-cell imaging analyses. Chromosome segregation analyses and colcemid challenge assays were performed on passage 5–6 primary MEFs stably expressing H2B2-mRFP, as previously described (15). Colcemid was added at 0.5 μg/mL (Karyomax, Gibco, catalog 15210-040). At least 23 and 10 cells per line were analyzed for chromosome segregation and colcemid challenge assays, respectively.

Analysis of age-related phenotypes. Mouse cohorts for lifespan and healthspan studies were generated, and animals were evaluated biweekly for cataracts and kyphosis as previously described (9). For evaluation of survival and cancer deaths, moribund mice were euthanized and all major organs were screened grossly for overt tumors, as previously described (9). Exercise ability by treadmill testing was performed and work output was calculated as previously described (10). Forelimb grip strength testing was performed as previously described (49). Body composition and total body fat were determined using an EchoMRI-100 QNMR instrument (Echo Medical Systems), as previously described (49). Total body lean and fat mass were recorded, and total body fat percentages were determined by dividing fat mass by body mass. Bone mineral density (BMD) was determined with dual-energy x-ray absorptiometry scanning (Lunar PIXIImus densitometer), as previously described (49). Cardiac stress tolerance was assessed using a chronic isoproterenol test, similarly to previously described studies (13). Terminal healthspan analyses of fat depot weights and collection of fat and skeletal muscle were performed as previously described (8, 9). Fat depot weights were normalized to the length of the right femur. Skeletal muscle (gastrocnemius) and fat (IAT) were fixed in 10% normal buffered formalin, embedded in paraffin, and 5-μm sections were stained with hematoxylin and eosin (H&E) as previously described (9). Skeletal muscle (gastrocnemius) fiber and fat (IAT) adipocyte sizes were determined as previously described (9), with the following modifications: cross-sectional area measurements of 150 fibers and adipocytes were made using ImageJ software. The mean of these measurements was then obtained per sample, and individual means were then averaged per group.

Tumor analyses. For spontaneous tumor analyses, mice were maintained until 18–20 months of age, and were then euthanized and grossly examined for overt tumors in all major organs, as described above. Carcinogen-induced tumorigenesis studies were performed with administration of DMBA as previously described (45). We note that studies on BubR1+/L1002P and BubR1++/ mice were conducted several years apart and with different batches of DMBA, and that variation between experiments can be observed (~20%–55% lung tumor incidence, and ~0.65–2.2 average tumor numbers in wild-type mice). Animals were euthanized at 4 months of age, and screened for the presence of overt tumors, including skin and lung. All tumors were counted, and the longest diameter measured at the time of collection or from images taken at time of collection. Lung tumor volumes were calculated using diameter measurements as previously described (21). To assess the mitotic index of spontaneous lymphatic tumors, mitotic cells were visualized by IF labeling of 2 paraffin sections separated by 150 μm for pHH3 (EMD Millipore, catalog 06-570) as previously described (6, 47).

SA-β-gal staining. Whole-mount SA-β-gal staining on fat (IAT) was performed as previously described (13). At least 3 animals were analyzed.

RNA library preparation, sequencing, and bioinformatic analyses. RNA was extracted from fat tissue or gastrocnemius muscle from 8- to 10-month-old mice using the RNeasy lipid and fibrous tissue kits, respectively (Qiagen, catalog 74704 and 1023559), and from gastrocnemius muscles from 3-month-old mice using the RNeasy fibrous tissue kit: n = 4 BubR1+/+, BubR1H+/L1002P, and BubR1H++ mice for IAT; n = 4 BubR1++/ and BubR1H+/L1002P mice and n = 3 for BubR1H++ mice for 8- to 10-month-old gastrocnemius; and n = 3 BubR1+/+, BubR1H+/L1002P, and BubR1H+/H mice for 3-month-old gastrocnemius. Library preparation and RNA sequencing were performed as previously described.
Fastq files of paired-end reads were aligned with TopHat 2.0.14 to the UCSC reference genome mm10 using Bowtie2 2.2.6 with default parameters. Differential expression analyses were performed using R package DESeq2 1.10.1 after removing genes with average raw counts less than 10 (47). Genes with lfcMLE (unshrunken maximum likelihood estimate of log fold change produced by DESeq2) greater than 0.45 or less than −0.45, and FDR less than 0.05 were considered significantly differentially expressed. Functional enrichment analyses for DEGs from the 3-month-old monoallelic skeletal muscle samples was performed using the STRING database, version 11 (https://string-db.org; ref. 25). Biological processes with FDR less than 0.05 were considered significantly enriched, and were classified into functional groups. For 8- to 10-month-old biallelic skeletal muscle and fat samples, putative SASP factor genes were extracted from the Gene Ontology Consortium (Mus musculus MGI), and QuickGO database for the annotation GO:0005615 “Extracellular Space” (30, 50, 51). Gene lists from both reference databases were merged, resulting in the identification of 1845 factors. SASP gene lists were then compared to differentially upregulated gene lists. Heatmaps were generated with Morpheus (Broad Institute; https://software.broadinstitute.org/morpheus). For p16/p19 (Cdkn2a) expression heatmaps row Z-scores were used, and for putative SASP factor and mTORC1-related gene expression heatmaps lfcMLE values were used.

Statistics. Statistical significance was determined using the log-rank test, 2-tailed Fisher’s exact test, 1-way ANOVA with a Holm-Sidak post hoc test, 2-tailed unpaired t test, and Mann-Whitney U test as noted in the figure legends. For 1-way ANOVA with Holm-Sidak correction for multiple comparisons, all groups were compared, with the exception of Figure 2E; Figure 3, A-D; Supplemental Figure 2A; and Supplemental Figure 5 where groups were compared to wild-type controls only, and where select comparisons were made (Supplemental Figure 2, C and E) as noted in the legends. All tests were performed using GraphPad Prism software, except for the 2-tailed unpaired t test, which was performed using Microsoft Excel. A P value less than 0.05 was considered statistically significant. Sample sizes for all animal studies were chosen based on previously published studies in which differences were observed. The experiments were not randomized, and the investigators were not blinded.

Study approval. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the Mayo Clinic, Rochester, Minnesota (protocol A00002189).

Data availability. RNA sequencing and single-cell DNA sequencing data have been deposited into the National Center for Biotechnology Information’s Gene Expression Omnibus under the accession numbers GSE134781 (3-month-old monoallelic skeletal muscle data) and GSE134780 (8- to 10-month-old biallelic skeletal muscle and fat data) and into the European Nucleotide Archive under the accession number PRJEB33810.

Author contributions. JMVD, CJS, HL, CZ, and DJB designed the research studies. CJS, KBJ, GGN, DJB, IS, CZ, and WHVD performed experiments. FF and BB performed karyotyping via single-cell whole-genome sequencing. All authors contributed to the analysis and interpretation of data. JMVD and CJS wrote the manuscript, and all authors edited the manuscript. JMVD directed and supervised all aspects of the study.

Acknowledgments. We thank Liviu Malureanu for initiating the project and the members of the van Deursen lab for helpful discussions, feedback, or help with methods. We thank the Cytogenetics and Sequencing Cores of the Medical Genome Facility, Mayo Clinic, for sample processing and technical support. This work was supported by grants from the NIH (R01 CA096985) and the Glenn Foundation for Medical Research to JMVD.

Address correspondence to: Jan M. van Deursen, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, USA. Phone: 507.284.2524; Email: vandeursen.jan@mayo.edu.


